{
    "clinical_study": {
        "@rank": "78825", 
        "acronym": "BPR", 
        "arm_group": [
            {
                "arm_group_label": "Barrett's Esophagus/Esophageal Adenocarcinoma", 
                "description": "Patients who have Barrett's esophagus or esophageal adenocarcinoma."
            }, 
            {
                "arm_group_label": "Healthy control"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum (from whole blood), plasma (from whole blood), tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The ultimate goal of the Barrett's Esophagus Patient Registry is to help develop more\n      effective targeted screening strategies and treatment options for Barrett's esophagus and\n      esophageal adenocarcinoma (EAC). We plan to do by developing a registry that will serve as a\n      platform.  Examples of analyses could include identifying genetic determinants and\n      biomarkers that predict BE, progression of BE to EAC, as well as the response to therapies."
        }, 
        "brief_title": "Barrett's Esophagus Patient Registry", 
        "completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Barrett Esophagus", 
            "Esophageal Adenocarcinoma", 
            "Gastroesophageal Reflux"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Barrett Esophagus", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Barrett's (BE): Patients who have Barrett's esophagus (all stages: Barrett's\n             metaplasia, low-grade dysplasia, high-grade dysplasia) based upon standard endoscopic\n             and histologic criteria.\n\n          -  Adenocarcinoma (EAC): Patients who have esophageal adenocarcinoma.\n\n          -  The control cohort will include patients ages 18 and older with no prior history of\n             BE and EAC. These may include patients who are being seen or have been previously\n             seen at MGH GI Associates for conditions including gastroesophageal reflux disease,\n             peptic esophagitis, eosinophilic esophagitis, esophageal motility disorders such as\n             achalasia and nutcracker esophagus.\n\n        Exclusion Criteria:\n\n          -  Inability or unwillingness to provide blood samples.\n\n          -  History of known bleeding disorders.\n\n          -  Currently awaiting organ transplantation.\n\n          -  Having an acute or severe chronic illness such as congestive heart failure or any\n             other condition that would prohibit performing the endoscopy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who have been seen at Massachusetts General Hospital."
            }
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776346", 
            "org_study_id": "2010P002224"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2013", 
        "location": {
            "contact": {
                "email": "kperzan@partners.org", 
                "last_name": "Katherine Perzan, BA", 
                "phone": "617-726-1431"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Barrett's Esophagus Patient Registry", 
        "overall_contact": {
            "email": "kperzan@partners.org", 
            "last_name": "Katherine Perzan, BA", 
            "phone": "617-726-1431"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression to esophageal adenocarcinoma", 
            "safety_issue": "No", 
            "time_frame": "5 years (on average although follow-up will continue)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776346"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Chin Hur", 
            "investigator_title": "Principal Investigator; MD, MPH", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Identify and validate genetic determinants that predict progression of BE to EAC and predict response to BE therapy", 
                "safety_issue": "No", 
                "time_frame": "5 years on average"
            }, 
            {
                "measure": "Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases", 
                "safety_issue": "No", 
                "time_frame": "5 years on average"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "January 2013"
    }
}